Monthly Writings

Evaluations and reviews of the latest in the field.

Clinical AI Post-Deployment Fragility

After reading this article, you will be able to describe why initial validation data does not guarantee post-deployment reliability and proposed solutions forearly identification.

SUMMARY:

  • Pre-deployment validation is common for safety and effectiveness, but it does not guarantee stability post-deployment.

  • Once incorporated into varying everyday clinical workflows, the potential for performance degradation exists.

  • Appropriate monitoring strategies for early identification of signal deterioration are key to maintaining desired outcomes.


Validation Approaches

  • Static Validation: As models are developed, testing on retrospective data is used as evidence of reliability.

  • Practice Validation: 3 forms

    • Internal validation: Sample set differs from algorithm training data

    • Temporal Validation: Data from a later time window within the same system

    • External Validation: Differing settings

Dataset Shift:

  • Clinical algorithm deployment rarely preserves the initial conditions they were introduced into.

  • Healthcare dataset shifting may occur due to :

    • Changes in care delivery workflows

    • Documentation processes

    • Clinical incentives

    • Random variation

  • This creates the opportunity for silent, slow performance degradation

Terms

  • Discrimination:

    • Ability to identify patients who will vs will not experience the outcome

    • Rank patients based on risk level

  • Calibration:

    • Demonstrates if the model's predictions are numerically accurate.

    • Prediction slope = Indicates if predictions are too extreme or modest; ideal = 1

    • Prediction Intercept = Indicates if predictions are too high or low, ideal = 0

Are There Early Signals of Model Degradation?

 Kopanitsa G (2026) Validation is not enough: Longitudinal evidence of post-deployment fragility in clinical AI systems. PLOS Digit Health 5(7): e0001534. https://doi. org/10.1371/journal.pdig.0001534

  •  Longitudinal, retrospective, observational study

  • 3 phases: Internal validation; early deployment (first 6 months); Late Deployment (after 6 months)

  • 4 clinically deployed AI systems:

    • A & B: High-frequency EHR predictive acute care models

    • C: Lab & Diagnostic outpatient decision support model

    • D: Imaging risk model outcome

  • 68,000 1,240,00 events from 18-24 months

RESULTS:

  • Performance degradation occurred with unchanged model parameters

  • Calibration changed earlier and more consistently than discrimination (AUROC)

  • Systems A & B had early calibration changes with negligible AUROC changes

  • With late deployment, calibration degradation was more pronounced

  • Discrimination (AUROC) demonstrated a stronger and more consistent deterioration with late deployment

Why Does Post-Implementation Degradation Happen (without model or population changes)?

  • Calibration drift over time was associated with:

  • Missingness: Missing model inputs at the expected time

  • Due to information availability to the model

  • Mainly from time-sensitive inputs (EHR inputs, vital signs, laboratory values, structured documentation fields of clinical workflow)

  • Data Latency

Implications:

  • Early changes in calibration make inaccurate estimates about absolute risk

  • Lack of changes in early AUROC may inappropriately preserve patient rankings

  • This could lead to delayed clinical deterioration since the AUROC remains in the acceptable range

  • Operational changes in data gathering, documentation and availability are the primary causes.

 PROPOSED SOLUTIONS:

  • Initial validation of the model is not enough

  • Calibration measurements should be repositioned as a safety measure with regularly repeated measurements post-deployment

  • This will be an early and greater monitoring signal for early triage and warnings versus outcome measures.

  • This adds to but does not replace outcome evaluations

CONCLUSIONS:

  • A one-time clinical validation does not provide ongoing assurance of model reliability.

    • Outcomes or AUROC changes may not initially detect changes in outcomes.

    • Calibration measurements should be added as repeat metrics post-deployment

    • A robust monitoring strategy should be designed for early identification of shifting early warning signals.

Pre-deployment clinical validation is common for safety and effectiveness.

  • However, ongoing clinical deployment rarely preserves the initial validation conditions, resulting in the potential for data shift.

  • Initial validation results cannot guarantee ongoing reliability.

  • The ability to predict accurate probabilities can change BEFORE the ability to discriminate threshold alert warnings of who will or will not experience an outcome.


Let’s have a brief chat to discuss your unique situation

Erkan Hassan